[1]Treatment outcomes in metastatic prostate cancer patients with DNA damage repair mutations. Daniel Kwon, et al., 2020 ASCO GU. Abstract 187.
[2]Propensity score matched comparison of docetaxel and androgen receptor axis-targeted (ARAT) agents in castration-resistant prostate cancer patients with intraductal carcinoma of the prostate (IDC-P). Akiyuki Yamamoto, et al., 2020 ASCO GU. Abstract 80.[3]Lang, S., et al. "A systematic review of the prevalence of DNA damage response gene mutations in prostate cancer." International Journal of Oncology. (2019).55:597-616[4]Wei, Y. "Germline DNA Repair Gene Mutation Landscape in Chinese Prostate Cancer Patients." EUROPEAN UROLOGY(2019). 76: 280-283.[5]Annala, M., et al. "Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair–deficient Prostate Cancer." EUROPEAN UROLOGY(2017). 72(1): 34-42.[6]Antonarakis, E. S., et al. "Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide." EUROPEAN UROLOGY(2018). 74(2): 218-225.[7]Velho, P. I., et al., "Intraductal/ductal histology and lymphovascular invasion are associated with germline DNA-repair gene mutations in prostate cancer." Prostate(2018). 78(5): 401-407.[8]Porter, L. H., et al., "Systematic Review Links the Prevalence of Intraductal Carcinoma of the Prostate to Prostate Cancer Risk Categories." EUROPEAN UROLOGY. (2017).[9]Comparision of docetaxel and androgen receptor axis-targeted(ARAT) agents for metastatic castration-resistant prostate cancer(mCRPC) patients with intraductal carcinoma of the prostate(IDC-P). Masashi keto, et al., EAU 2019. Poster #899.[10]Gillessen S, et al. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur Urol (2017)[11]Khalaf, D. J., et al. "Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial." The Lancet Oncology(2019). 20(12): 1730-1739.[12]Chung, D. Y., et al. "Comparison of Oncologic Outcomes between Two Alternative Sequences with Abiraterone Acetate and Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis." Cancers(2019). 12(1): 8.